文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤放疗物理与技术

磁共振引导前列腺、盆腔及转移灶同步多靶区自适应放疗的前瞻性II期研究

Magnetic resonance-guided simultaneous multi-focal adaptive radiotherapy for prostate, pElvis & metastases (MRgSMART-PEM) in prostate cancer: a prospective phase II study.
PubMed 文献 · Radiat Oncol · 2026-02-13

该前瞻性单臂II期研究纳入35例高危、极高危或寡转移性前列腺癌患者,采用1.5-T MR-Linac实施MRgSMART-PEM,隔日5次、Adapt-to-Shape流程。主要终点为12周内急性≥2级泌尿生殖和胃肠道毒性,结果为各5.7%,未见晚期≥2级毒性;2年生化与临床无进展生存率均为87.4%,野内控制率100%。

要点

  • 急性≥2级GU与GI毒性各为5.7%,含1例3级GI事件且8周内均缓解
  • 中位随访17.2个月未见晚期≥2级毒性,生活质量3个月恢复至基线
  • 2年生化与临床无进展生存率均为87.4%,野内控制率100%

核心结论

  • MRgSMART-PEM在高危、极高危及寡转移性前列腺癌患者中可行、安全且耐受良好,局部控制优异、毒性轻微且生活质量恢复,支持进一步开展随机试验验证。

研究设计与样本

  • 前瞻性单臂II期研究,纳入35例病理确诊前列腺癌患者(11例局限、8例盆腔淋巴结、16例寡转移)。
  • 2021年6月至2025年3月在1.5-T MR-Linac上实施MRgSMART-PEM,隔日5次、Adapt-to-Shape工作流程。
  • 主要终点为12周内临床医生报告的急性≥2级泌尿生殖(GU)和胃肠道(GI)毒性;次要终点包括晚期毒性、生活质量与生存结局。
  • 试验注册号NCT05183074(中国医学科学院,2022-01-10首次发布)。

主要发现

  • 中位随访17.2个月(范围4.3–49.3),中位治疗床时间59分钟(范围35–80)。
  • 急性≥2级GU和GI毒性均见于5.7%的患者,含1例3级GI事件,均在8周内缓解。
  • 未观察到晚期≥2级毒性,无1级事件持续超过18个月。
  • 生活质量评分在治疗后2周下降,3个月恢复至基线。
  • 2年时生化与临床无进展生存率均为87.4%,野内控制率为100%。

关键数值与推荐

  • 主要终点:12周内急性≥2级GU毒性5.7%、GI毒性5.7%(35例患者中)。
  • 晚期毒性:无≥2级事件,无1级事件持续超过18个月。
  • 2年生化与临床无进展生存率均为87.4%,野内控制率100%。
  • 生活质量:治疗后2周下降,3个月恢复至基线。

临床怎么用

  • 该方案在1.5-T MR-Linac上隔日5次实施,中位床旁时间59分钟,可作为高危及寡转移前列腺癌同步多靶区放疗的可行选择。
  • 治疗期间需关注急性GU与GI毒性,本研究显示多可于8周内缓解,但需警惕偶发3级GI事件。
  • 治疗前2周生活质量可能下降,应向患者说明3个月内多可恢复至基线。
  • 2年野内控制率100%提示局部控制良好,但仍需随机试验进一步验证。
  • 研究未报告具体剂量分割参数,临床实施需结合本机构流程确定。

局限性

  • 单臂设计、样本量35例,缺乏对照组,结论需随机试验验证。
  • 中位随访仅17.2个月,晚期毒性与生存数据尚不成熟。
  • 单中心研究,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the safety, feasibility, and patient-reported outcomes of magnetic resonance-guided simultaneous multi-focal adaptive radiotherapy for the prostate, pelvis, and metastases (MRgSMART-PEM) in patients with high-risk, very-high-risk, or oligometastatic prostate cancer. METHODS AND MATERIALS: In this prospective single-arm phase II study, 35 patients with pathologically confirmed prostate cancer (11 localized, 8 pelvic nodal, 16 oligometastatic) were treated with MRgSMART-PEM on a 1.5-T MR-Linac between June 2021 and March 2025. Radiotherapy was delivered in five alternate-day fractions using an Adapt-to-Shape workflow. The primary endpoint was clinician-reported acute grade ≥ 2 genitourinary (GU) and gastrointestinal (GI) toxicity within 12 weeks. Secondary endpoints included late toxicity, quality of life (QoL), and survival outcomes. RESULTS: Median follow-up was 17.2 months (range, 4.3–49.3). The median on-couch time was 59 min (range, 35–80). Acute grade ≥ 2 GU and GI toxicities occurred in 5.7% of patients each, including one grade 3 GI event; all resolved within 8 weeks. No late grade ≥ 2 toxicities were observed, and no grade 1 events persisted beyond 18 months. QoL scores declined at 2 weeks post-treatment but returned to baseline by 3 months. At 2 years, biochemical and clinical progression-free survival rates were both 87.4%, and in-field control was 100%. CONCLUSIONS: MRgSMART-PEM is feasible, safe, and well tolerated in patients with high-risk, very-high-risk, and oligometastatic prostate cancer, achieving excellent local control with minimal toxicity and recovery of QoL. These results support further evaluation of MRgSMART-PEM in randomized trials. TRIAL REGISTRATION: NCT05183074 (Chinese Academy of Medical Sciences, First Posted 2022-01-10).

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Sun M, Qin SR, Wei R, et al. Magnetic resonance-guided simultaneous multi-fo​cal adaptive radiotherapy for prostate, pElvis & metastases (MRgSMART-PEM) in prostate cancer: a prospective phase II study. Radiat Oncol. 2026. PMID: 41689033. doi:10.1186/s13014-026-02799-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。